Session XX: Presentation of Selected Abstracts: Metastatic Colorectal Cancer

Chair(s)

• 

  Irit Ben-Aharon, MD, PhD

  Rambam Health Care Campus
  Haifa, Israel
• 

  Per Pfeiffer

  Odense University Hospital
  Odense, Denmark

Presentations:

• 08:00 – 08:08 CEST

  SO-24: Panitumumab plus trifluridine/tipiracil as anti-EGFR rechallenge therapy in patients with refractory RAS wild-type metastatic colorectal cancer: overall survival and subgroup analysis of the randomized phase 2 VELO trial
  

  Abstract Presenter: Davide Ciardiello
• 08:08 – 08:16 CEST

  SO-25: Modified (m)-FOLFOXIRI plus cetuximab versus m-FOLFOXIRI plus bevacizumab as initial treatment for RAS and BRAF wild-type metastatic colorectal cancer: Updated survival analysis of the DEEPER trial by JACCRO
  

  Abstract Presenter: Yu Sunakawa, MD, PhD – St. Marianna University School of Medicine
• 08:16 – 08:24 CEST

  SO-26: Intermittent or continuous panitumumab plus FOLFIRI for first-line treatment of patients with RAS/BRAF wild-type metastatic colorectal cancer: an update of survival/toxicity and preliminary results of genomic alterations from IMPROVE study
  

  Abstract Presenter: Alfonso De Stefano
• 08:24 – 08:32 CEST

  SO-27: Modified FOLFOXIRI plus cetuximab and avelumab as initial therapy in RAS wild-type unresectable metastatic colorectal cancer: results of the phase II AVETRIC trial by GONO
  

  Abstract Presenter: Veronica Conca
• 08:32 – 08:42 CEST

  Discussant: SO-24, SO-25, SO-26, SO-27
  

  Discussant: Shouki Bazarbashi, MBBS – King Faisal Specialist Hospital and Research Center-Riyadh
• 08:42 – 08:50 CEST

  SO-28: FOLFOXIRI plus bevacizumab and atezolizumab as upfront treatment of unresectable mCRC patients: updated and overall survival results of the phase II randomized AtezoTRIBE study
  

  Abstract Presenter: Carlotta Antoniotti
• 08:50 – 08:58 CEST

  SO-29: Clinical characteristics, efficacy, and safety in patients receiving second- or third-line encorafenib plus cetuximab (E+C) vs control for metastatic colorectal cancer (mCRC): BEACON CRC post hoc analysis
  

  Abstract Presenter: Josep Tabernero, MD – Vall d’Hebron University Hospital
• 08:58 – 09:06 CEST

  SO-30: RAS status in circulating-tumor DNA after chemotherapy in RAS mutant mCRC: the RASMEX study (JACCRO CC-17)
  

  Abstract Presenter: Shinichi Nishina
• 09:06 – 09:14 CEST

  SO-31: Comprehensive genomic profiling of tumor tissue and plasma circulating tumor DNA in RAS/BRAFV600E wild type metastatic colorectal cancer patients: initial findings from the CAPRI 2-GOIM trial
  

  Abstract Presenter: Giulia Martini
• 09:14 – 09:25 CEST

  Discussant: SO-28, SO-29, SO-30, SO-31
  

  Discussant: Pia Osterlund, MD, PhD, Prof – Tampere and Kaolinska University Hospitals; Karolinska Institutet